中国组织工程研究Issue(11)：2007-2012,6.DOI:10.3969/j.issn.2095-4344.2013.11.016
Ⅱ型胶原注射骨关节炎时C-反应蛋白及类风湿因子的表达*★
Expression of rheumatoid factor and C-reactive protein during type Ⅱ collagen treatment of osteoarthritis
摘要
Abstract
BACKGROUND: Type Ⅱ col agen and chondroitin sulfate are the major components of articular cartilage. They cannot only protect the cartilage, but also inhibit pathology of osteoarthritis. OBJECTIVE: To evaluate the curative effect of type Ⅱ col agen injection and type Ⅱ col agen-chondroitin sulfate composite injection on osteoarthritis by detecting the expression of rheumatoid factor and C-reactive protein. METHODS: A rat model of knee osteoarthritis was established by using improved Hulth’s method. The treatment was performed via injection into the articular cavity (treatment group A: type Ⅱ col agen injection;treatment group B: type Ⅱ col agen-chondroitin sulfate composite injection; positive control: sodium hyaluronate; model control: physiological saline). After operation, rats in each group were characterized with daily observation, weighing, serum antibody test and histological observation. RESULTS AND CONCLUSION: After treatment, the content of rheumatoid factor and C-reactive protein in rats’ serum of model group was increased, and inflammation was aggravated; while compared with the model group, the content of rheumatoid factor and C-reactive protein in the other groups, especial y in the treatment group B, were lower and the inflammation was eased (P < 0.01). The findings show that both type Ⅱ col agen and sodium hyaluronate can prevent and treat osteoarthritis effectively. The therapeutic effect of type Ⅱ col agen combined with chondroitin sulfate is better.关键词
组织构建/组织构建基础实验/Ⅱ型胶原/硫酸软骨素/骨性关节炎/类风湿因子/C-反应蛋白/透明质酸钠/动物模型/改良 Hulth 法/炎症/软骨病变/省级基金/组织构建图片文章分类
医药卫生引用本文复制引用
雷静,钟翠红,陈淡嫦,黄雷..Ⅱ型胶原注射骨关节炎时C-反应蛋白及类风湿因子的表达*★[J].中国组织工程研究,2013,(11):2007-2012,6.基金项目
广东省科技计划项目-社会发展专项(2009B030803060)。Supported by：the Science and Technology Plan of Guangdong Province (Special Fund for the Social Development), No.2009B030803060* （2009B030803060）
